Cargando…
Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate
Hepatitis C virus (HCV) is a global disease burden, and a preventive vaccine is needed to control or eradicate the virus. Despite the advent of effective antiviral therapy, this treatment is not accessible to many patients and does not prevent reinfection, making chronic hepatitis C an ongoing globa...
Autores principales: | Wang, Ruixue, Suzuki, Saori, Guest, Johnathan D., Heller, Brigitte, Almeda, Maricar, Andrianov, Alexander K., Marin, Alexander, Mariuzza, Roy A., Keck, Zhen-Yong, Foung, Steven K. H., Yunus, Abdul S., Pierce, Brian G., Toth, Eric A., Ploss, Alexander, Fuerst, Thomas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931252/ https://www.ncbi.nlm.nih.gov/pubmed/35263223 http://dx.doi.org/10.1073/pnas.2112008119 |
Ejemplares similares
-
Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development
por: Toth, Eric A., et al.
Publicado: (2021) -
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells
por: Urbanowicz, Richard A., et al.
Publicado: (2019) -
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
por: Metcalf, Matthew C., et al.
Publicado: (2023) -
Fluorine-Functionalized Polyphosphazene Immunoadjuvant: Synthesis, Solution Behavior and In Vivo Potency
por: Tagad, Harichandra D., et al.
Publicado: (2023) -
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein
por: Owsianka, Ania M., et al.
Publicado: (2008)